क्लिनिकल परीक्षण जर्नल

क्लिनिकल परीक्षण जर्नल
खुला एक्सेस

आईएसएसएन: 2167-0870

अमूर्त

Regulation of Bile Acids by an NTCP Inhibitor is Promising for the Treatment of Nonalcoholic Steatohepatitis

Cuili Fan, Hongli Liu*, Jian Wu*

The beneficial effects of Hepalatide, an inhibitor of sodium taurocholate cotransporting polypeptide (NTCP), on the progression of nonalcoholic steato hepatitis was previously validated in mice. The underlying mechanismsare presumably associated with the profile changes of bile acids, which are natural agonistsfor FXR and TGR5receptors. In this short communication, the profile of bile acids and the metabolic changes in the liver or peripheral tissues were analyzed. It is our anticipation that using NTCP inhibitors, such as Hepalatide for the nonalcoholic steatohepatitis would be a clinically-applicable strategy

अस्वीकरण: इस सार का अनुवाद कृत्रिम बुद्धिमत्ता उपकरणों का उपयोग करके किया गया था और अभी तक इसकी समीक्षा या सत्यापन नहीं किया गया है।
Top